| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 12, 2007
Accepted on December 26, 2007
Centre for Endocrinology, Barts & the London, Queen Mary University of London, London EC1M 6BQ, UK
* To whom correspondence should be addressed. E-mail: p.j.king{at}qmul.ac.uk.
The role of ACTH in stimulating or inhibiting growth of adrenal cells has been a subject of some controversy. Reports that ACTH may stimulate ERK/MAP kinase in Y1 cells have suggested a role for cAMP in this process. In attempting to extend this work, the ACTH responses in the human H295R cell line have been studied. This cell line makes only a very modest cAMP response to ACTH, yet the ERK1/2 response is highly reproducible and immediate, but not prolonged. It is minimally reduced by the protein kinase A inhibitor, H89, but unaffected by PKC and calcium inhibitors. Inhibition of EGF receptor or other tyrosine kinase receptor transactivation was without effect, as was inhibition of c-Src activity or c-Src phosphorylation. The most effective inhibitor of this pathway was dansylcadaverine, an inhibitor of receptor internalization. These findings imply that ACTH-induced ERK1/2 activation in H295R cells is dependent on a mechanism distinct from that by which most G protein-coupled receptors activate ERK1/2, but which nevertheless seems to depend on receptor internalization.
This article has been cited by other articles:
![]() |
J. Parmar, R. E. Key, and W. E. Rainey Development of an Adrenocorticotropin-Responsive Human Adrenocortical Carcinoma Cell Line J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4542 - 4546. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |